Psoriasis

Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women’s Connection Forum.

Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.

In an AAD late-breaking research session, Joel Gelfand, MD, MSCE, FAAD, presented in-depth results of the LITE Study.

Psoriasis is linked to a heightened risk of cardiovascular disease, necessitating proactive screening, collaborative care, and consideration of potential impacts of psoriasis treatments on cardiovascular health.

As a pharmacy benefit manager, Livinti will help reduce biologic drug costs for self-funded employees.

A recent study identified an association between psoriasis severity and IBD, Crohn disease, and ulcerative colitis.

Biologics to treat psoriasis can cost between $1664 and $79,277 a year in the United States, one study found, and these prices are not commensurate with clinical benefits.

Get a sneak peek ahead of AAD about the LITE study’s patient-centered design, routine care integration, and diverse participant inclusion, offering a cost-effective option in psoriasis treatment.

Findings reveal an increased risk of psoriatic arthritis among female patients with severe skin psoriasis who have nail involvement and require oral systemic therapy for their condition.

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.

Joel Gelfand, MD, explained how body surface area on patients with psoriasis plays a pivotal role in cardiovascular outcomes.

Alice Gottlieb, MD, PhD, put a spotlight on recent studies and the current psoriasis treatment armamentarium for dermatology clinicians to consider.

The IFPA Forum Roadmap for Asia outlines key advocacy demands and practical strategies to improve psoriatic care throughout the continent.

Artax announced that safety and efficacy data is expected in the second half of the year.

A new study suggests patients with psoriasis may experience exacerbated disease burden waiting to initiate systemic treatment.

Data from the FRONTIER 1 clinical trial were recently published in the New England Journal of Medicine.

The VISIBLE clinical program will create a longitudinal collection of more than 20,000 clinical images across all skin tones.

New evidence identifies factors that may predict which patients with psoriasis will develop psoriatic arthritis.

This article will highlight recently approved psoriasis therapies that will shape the 2024 treatment landscape and provide some exciting updates in the psoriasis management market this coming year and beyond.

A recent retrospective cohort study described drug survival and treatment patterns among patients with newly-diagnosed generalized pustular psoriasis.

When examining Ezra’s skin, you note well-defined erythematous scaly plaques with well-defined, serpiginous, raised borders and yellow crusting on the anterior shins and forearms.

Researchers say that application of these findings in clinical settings could enhance treatment optimization.

Drs Lisa Swanson and Robert J. Casquejo express their optimism for the future of plaque psoriasis management, sharing their vision for expanded treatment approvals in the pediatric population affected by this condition.

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Experts in dermatology emphasize the need to consider patients' overall well-being when evaluating the safety profiles of emerging biologic treatments for plaque psoriasis, taking into account the heightened levels of depression and anxiety in individuals with this condition.

George Han, MD, discusses the latest biologic agents for plaque psoriasis, addressing the balance between efficacy and speed of response. Together with Dr. Leon Kircik, they emphasize the significance of comprehensive data for physician confidence and delve into the clinical utilization of these treatments, stressing the importance of baseline laboratory measurements for all prescribed patients.

Leon Kircik, MD, emphasizes the combined use of emerging topical treatments with systemic or biologic medications and the impact of the treatment vehicle on penetration. He also discusses the potential for longer use of steroidal options by reducing active product quantities through better penetrating vehicles and highlights the potential heightened efficacy of newer topical treatments and the gaps they may fill in the management of this condition.

The topical therapy was more effective in patients with psoriasis and AD when compared to a vehicle control cream.

A meta-analysis revealed that a post-operative care routine that involves psychological well-being leads to improved patient outcomes.

Soligenix shared today positive top-line data stemming from the phase 2a clinical trial.